Biologically Active Oligodeoxyribonucleotides. 5. 5‘-End-Substituted d(TGGGAG) Possesses Anti-Human Immunodeficiency Virus Type 1 Activity by Forming a G-Quadruplex Structure
Identifieur interne : 003A90 ( Main/Exploration ); précédent : 003A89; suivant : 003A91Biologically Active Oligodeoxyribonucleotides. 5. 5‘-End-Substituted d(TGGGAG) Possesses Anti-Human Immunodeficiency Virus Type 1 Activity by Forming a G-Quadruplex Structure
Auteurs : Hitoshi Hotoda [Japon] ; Makoto Koizumi [Japon] ; Rika Koga [Japon] ; Masakatsu Kaneko [Japon] ; Kenji Momota [Japon] ; Toshinori Ohmine [Japon] ; Hidehiko Furukawa [Japon] ; Toshinori Agatsuma [Japon] ; Takashi Nishigaki [Japon] ; Junko Sone [Japon] ; Shinya Tsutsumi [Japon] ; Toshiyuki Kosaka [Japon] ; Koji Abe [Japon] ; Satoshi Kimura [Japon] ; Kaoru Shimada [Japon]Source :
- Journal of Medicinal Chemistry [ 0022-2623 ] ; 1998.
Descripteurs français
- KwdFr :
- Agents antiVIH (), Agents antiVIH (pharmacologie), Agents antiVIH (sang), Agents antiVIH (synthèse chimique), Conformation moléculaire, Dichroïsme circulaire, Humains, Lignée de cellules transformées, Oligodésoxyribonucléotides (), Oligodésoxyribonucléotides (pharmacologie), Oligodésoxyribonucléotides (sang), Oligodésoxyribonucléotides (synthèse chimique), Relation structure-activité, Solutions, Stabilité de médicament, VIH-1 (Virus de l'Immunodéficience Humaine de type 1) ().
- MESH :
- pharmacologie : Agents antiVIH, Oligodésoxyribonucléotides.
- sang : Agents antiVIH, Oligodésoxyribonucléotides.
- synthèse chimique : Agents antiVIH, Oligodésoxyribonucléotides.
- Agents antiVIH, Conformation moléculaire, Dichroïsme circulaire, Humains, Lignée de cellules transformées, Oligodésoxyribonucléotides, Relation structure-activité, Solutions, Stabilité de médicament, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- Pascal (Inist)
- Antiviral, Appariement base, Arène, Benzène dérivé, DNA antisens, Dichroïsme circulaire, Désoxyribonucléotide, Extrémité 5′ P, Fluorène dérivé, Homme, Hybridation moléculaire, In vitro, Liquide biologique, Longueur chaîne, Modification chimique, Naphtalène dérivé, Oligodésoxyribonucléotide, Plasma sanguin, Pyrène dérivé, Relation structure activité, Stabilité chimique, Synthèse chimique, Virus HIV1, Xanthène dérivé, d(T-G-G-G-A-G).
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- 5′-End, Anti-HIV Agents (blood), Anti-HIV Agents (chemical synthesis), Anti-HIV Agents (chemistry), Anti-HIV Agents (pharmacology), Antisense DNA, Antiviral, Arene, Base pairing, Benzene derivatives, Biological fluid, Blood plasma, Cell Line, Transformed, Chain length, Chemical modification, Chemical stability, Chemical synthesis, Circular Dichroism, Circular dichroism, Deoxyribonucleotide, Drug Stability, Fluorene derivatives, HIV-1 (drug effects), HIV-1 virus, Human, Humans, In vitro, Molecular Conformation, Molecular hybridization, Naphthalene derivatives, Oligodeoxyribonucleotide, Oligodeoxyribonucleotides (blood), Oligodeoxyribonucleotides (chemical synthesis), Oligodeoxyribonucleotides (chemistry), Oligodeoxyribonucleotides (pharmacology), Pyrene derivatives, Solutions, Structure activity relation, Structure-Activity Relationship, Xanthene derivatives.
- MESH :
- chemical , blood : Anti-HIV Agents, Oligodeoxyribonucleotides.
- chemical , chemical synthesis : Anti-HIV Agents, Oligodeoxyribonucleotides.
- chemical , chemistry : Anti-HIV Agents, Oligodeoxyribonucleotides.
- chemical , pharmacology : Anti-HIV Agents, Oligodeoxyribonucleotides.
- drug effects : HIV-1.
- Cell Line, Transformed, Circular Dichroism, Drug Stability, Humans, Molecular Conformation, Solutions, Structure-Activity Relationship.
Abstract
A series of hexadeoxyribonucleotides (6-mers), d(TGGGAG), substituted with a variety of aromatic groups at the 5‘-end were synthesized and tested for anti-human immunodeficiency virus type 1 (HIV-1) activity. While unmodified d(TGGGAG) (31) had no anti-HIV-1 activity, compound 23 with a 3,4-di(benzyloxy)benzyl (DBB) group at the 5‘-end potently inhibited the HIV-1IIIB-induced cytopathicity of MT-4 cells in vitro (IC50 = 0.37 μM) without cytotoxicity up to 40 μM. A thermal denaturation study on the 5‘-end-substituted 6-mers by means of the circular dichroism (CD) spectra demonstrated that the aromatic substituent attached at the 5‘-end of the 6-mer strongly enhanced the formation of a parallel helical structure consisting of four strands (quadruplex). On the contrary, compound 36, in which one of the guanosines of 23 was replaced by a thymidine, did not form a quadruplex, thus exhibiting no anti-HIV-1 activity. Moreover, both compound 15, with a tert-butyldiphenylsilyl group solely at its 3‘-end, and compound 21, with a relatively small substituent, a benzyl group, at the 5‘-end, formed quadruplexes but had no anti-HIV-1 activity. These findings led us to the conclusion that both the quadruplex structure and the aromatic substituent with adequate size at the 5‘-end are crucial for the interaction of the 5‘-end-substituted 6-mers with the V3 loop as well as the CD4 binding site on viral gp120, resulting in anti-HIV-1 activity.
Url:
DOI: 10.1021/jm970658w
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000281
- to stream Istex, to step Curation: 000281
- to stream Istex, to step Checkpoint: 001299
- to stream PubMed, to step Corpus: 002670
- to stream PubMed, to step Curation: 002670
- to stream PubMed, to step Checkpoint: 002554
- to stream Ncbi, to step Merge: 002B33
- to stream Ncbi, to step Curation: 002B33
- to stream Ncbi, to step Checkpoint: 002B33
- to stream Main, to step Merge: 003B39
- to stream PascalFrancis, to step Corpus: 000097
- to stream PascalFrancis, to step Curation: 000116
- to stream PascalFrancis, to step Checkpoint: 000097
- to stream Main, to step Merge: 003C50
- to stream Main, to step Curation: 003A90
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Biologically Active Oligodeoxyribonucleotides. 5. 5‘-End-Substituted d(TGGGAG) Possesses Anti-Human Immunodeficiency Virus Type 1 Activity by Forming a G-Quadruplex Structure</title><author><name sortKey="Hotoda, Hitoshi" sort="Hotoda, Hitoshi" uniqKey="Hotoda H" first="Hitoshi" last="Hotoda">Hitoshi Hotoda</name></author><author><name sortKey="Koizumi, Makoto" sort="Koizumi, Makoto" uniqKey="Koizumi M" first="Makoto" last="Koizumi">Makoto Koizumi</name></author><author><name sortKey="Koga, Rika" sort="Koga, Rika" uniqKey="Koga R" first="Rika" last="Koga">Rika Koga</name></author><author><name sortKey="Kaneko, Masakatsu" sort="Kaneko, Masakatsu" uniqKey="Kaneko M" first="Masakatsu" last="Kaneko">Masakatsu Kaneko</name></author><author><name sortKey="Momota, Kenji" sort="Momota, Kenji" uniqKey="Momota K" first="Kenji" last="Momota">Kenji Momota</name></author><author><name sortKey="Ohmine, Toshinori" sort="Ohmine, Toshinori" uniqKey="Ohmine T" first="Toshinori" last="Ohmine">Toshinori Ohmine</name></author><author><name sortKey="Furukawa, Hidehiko" sort="Furukawa, Hidehiko" uniqKey="Furukawa H" first="Hidehiko" last="Furukawa">Hidehiko Furukawa</name></author><author><name sortKey="Agatsuma, Toshinori" sort="Agatsuma, Toshinori" uniqKey="Agatsuma T" first="Toshinori" last="Agatsuma">Toshinori Agatsuma</name></author><author><name sortKey="Nishigaki, Takashi" sort="Nishigaki, Takashi" uniqKey="Nishigaki T" first="Takashi" last="Nishigaki">Takashi Nishigaki</name></author><author><name sortKey="Sone, Junko" sort="Sone, Junko" uniqKey="Sone J" first="Junko" last="Sone">Junko Sone</name></author><author><name sortKey="Tsutsumi, Shinya" sort="Tsutsumi, Shinya" uniqKey="Tsutsumi S" first="Shinya" last="Tsutsumi">Shinya Tsutsumi</name></author><author><name sortKey="Kosaka, Toshiyuki" sort="Kosaka, Toshiyuki" uniqKey="Kosaka T" first="Toshiyuki" last="Kosaka">Toshiyuki Kosaka</name></author><author><name sortKey="Abe, Koji" sort="Abe, Koji" uniqKey="Abe K" first="Koji" last="Abe">Koji Abe</name></author><author><name sortKey="Kimura, Satoshi" sort="Kimura, Satoshi" uniqKey="Kimura S" first="Satoshi" last="Kimura">Satoshi Kimura</name></author><author><name sortKey="Shimada, Kaoru" sort="Shimada, Kaoru" uniqKey="Shimada K" first="Kaoru" last="Shimada">Kaoru Shimada</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:EDFEF0F4A1559CD2994984A74C246B4A86698F91</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1021/jm970658w</idno><idno type="url">https://api.istex.fr/ark:/67375/TPS-2GKC28BF-G/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000281</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000281</idno><idno type="wicri:Area/Istex/Curation">000281</idno><idno type="wicri:Area/Istex/Checkpoint">001299</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001299</idno><idno type="wicri:doubleKey">0022-2623:1998:Hotoda H:biologically:active:oligodeoxyribonucleotides</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:9733490</idno><idno type="wicri:Area/PubMed/Corpus">002670</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002670</idno><idno type="wicri:Area/PubMed/Curation">002670</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002670</idno><idno type="wicri:Area/PubMed/Checkpoint">002554</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002554</idno><idno type="wicri:Area/Ncbi/Merge">002B33</idno><idno type="wicri:Area/Ncbi/Curation">002B33</idno><idno type="wicri:Area/Ncbi/Checkpoint">002B33</idno><idno type="wicri:doubleKey">0022-2623:1998:Hotoda H:biologically:active:oligodeoxyribonucleotides</idno><idno type="wicri:Area/Main/Merge">003B39</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:98-0478975</idno><idno type="wicri:Area/PascalFrancis/Corpus">000097</idno><idno type="wicri:Area/PascalFrancis/Curation">000116</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000097</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000097</idno><idno type="wicri:doubleKey">0022-2623:1998:Hotoda H:biologically:active:oligodeoxyribonucleotides</idno><idno type="wicri:Area/Main/Merge">003C50</idno><idno type="wicri:Area/Main/Curation">003A90</idno><idno type="wicri:Area/Main/Exploration">003A90</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Biologically Active Oligodeoxyribonucleotides. 5.<ref type="bibr" target="#jm970658wb00001"></ref> 5‘-End-Substituted
d(TGGGAG) Possesses Anti-Human Immunodeficiency Virus Type 1 Activity by
Forming a G-Quadruplex Structure</title><author><name sortKey="Hotoda, Hitoshi" sort="Hotoda, Hitoshi" uniqKey="Hotoda H" first="Hitoshi" last="Hotoda">Hitoshi Hotoda</name><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Exploratory Chemistry Research Laboratories, Biological Research Laboratories, and Analytical and Metabolic ResearchLaboratories, Sankyo Company, Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan, and The Department ofInfectious Diseases, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku,Tokyo 108</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName><orgName type="university">Université de Tokyo</orgName><placeName><settlement type="city">Tokyo</settlement><region type="province">Région de Kantō</region></placeName></affiliation><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Japon</country></affiliation></author><author><name sortKey="Koizumi, Makoto" sort="Koizumi, Makoto" uniqKey="Koizumi M" first="Makoto" last="Koizumi">Makoto Koizumi</name><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Exploratory Chemistry Research Laboratories, Biological Research Laboratories, and Analytical and Metabolic ResearchLaboratories, Sankyo Company, Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan, and The Department ofInfectious Diseases, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku,Tokyo 108</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName><orgName type="university">Université de Tokyo</orgName><placeName><settlement type="city">Tokyo</settlement><region type="province">Région de Kantō</region></placeName></affiliation><affiliation></affiliation></author><author><name sortKey="Koga, Rika" sort="Koga, Rika" uniqKey="Koga R" first="Rika" last="Koga">Rika Koga</name><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Exploratory Chemistry Research Laboratories, Biological Research Laboratories, and Analytical and Metabolic ResearchLaboratories, Sankyo Company, Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan, and The Department ofInfectious Diseases, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku,Tokyo 108</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName><orgName type="university">Université de Tokyo</orgName><placeName><settlement type="city">Tokyo</settlement><region type="province">Région de Kantō</region></placeName></affiliation><affiliation></affiliation></author><author><name sortKey="Kaneko, Masakatsu" sort="Kaneko, Masakatsu" uniqKey="Kaneko M" first="Masakatsu" last="Kaneko">Masakatsu Kaneko</name><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Exploratory Chemistry Research Laboratories, Biological Research Laboratories, and Analytical and Metabolic ResearchLaboratories, Sankyo Company, Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan, and The Department ofInfectious Diseases, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku,Tokyo 108</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName><orgName type="university">Université de Tokyo</orgName><placeName><settlement type="city">Tokyo</settlement><region type="province">Région de Kantō</region></placeName></affiliation><affiliation></affiliation></author><author><name sortKey="Momota, Kenji" sort="Momota, Kenji" uniqKey="Momota K" first="Kenji" last="Momota">Kenji Momota</name><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Exploratory Chemistry Research Laboratories, Biological Research Laboratories, and Analytical and Metabolic ResearchLaboratories, Sankyo Company, Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan, and The Department ofInfectious Diseases, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku,Tokyo 108</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName><orgName type="university">Université de Tokyo</orgName><placeName><settlement type="city">Tokyo</settlement><region type="province">Région de Kantō</region></placeName></affiliation><affiliation></affiliation></author><author><name sortKey="Ohmine, Toshinori" sort="Ohmine, Toshinori" uniqKey="Ohmine T" first="Toshinori" last="Ohmine">Toshinori Ohmine</name><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Exploratory Chemistry Research Laboratories, Biological Research Laboratories, and Analytical and Metabolic ResearchLaboratories, Sankyo Company, Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan, and The Department ofInfectious Diseases, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku,Tokyo 108</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName><orgName type="university">Université de Tokyo</orgName><placeName><settlement type="city">Tokyo</settlement><region type="province">Région de Kantō</region></placeName></affiliation><affiliation></affiliation></author><author><name sortKey="Furukawa, Hidehiko" sort="Furukawa, Hidehiko" uniqKey="Furukawa H" first="Hidehiko" last="Furukawa">Hidehiko Furukawa</name><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Exploratory Chemistry Research Laboratories, Biological Research Laboratories, and Analytical and Metabolic ResearchLaboratories, Sankyo Company, Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan, and The Department ofInfectious Diseases, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku,Tokyo 108</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName><orgName type="university">Université de Tokyo</orgName><placeName><settlement type="city">Tokyo</settlement><region type="province">Région de Kantō</region></placeName></affiliation><affiliation></affiliation></author><author><name sortKey="Agatsuma, Toshinori" sort="Agatsuma, Toshinori" uniqKey="Agatsuma T" first="Toshinori" last="Agatsuma">Toshinori Agatsuma</name><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Exploratory Chemistry Research Laboratories, Biological Research Laboratories, and Analytical and Metabolic ResearchLaboratories, Sankyo Company, Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan, and The Department ofInfectious Diseases, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku,Tokyo 108</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName><orgName type="university">Université de Tokyo</orgName><placeName><settlement type="city">Tokyo</settlement><region type="province">Région de Kantō</region></placeName></affiliation><affiliation></affiliation></author><author><name sortKey="Nishigaki, Takashi" sort="Nishigaki, Takashi" uniqKey="Nishigaki T" first="Takashi" last="Nishigaki">Takashi Nishigaki</name><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Exploratory Chemistry Research Laboratories, Biological Research Laboratories, and Analytical and Metabolic ResearchLaboratories, Sankyo Company, Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan, and The Department ofInfectious Diseases, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku,Tokyo 108</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName><orgName type="university">Université de Tokyo</orgName><placeName><settlement type="city">Tokyo</settlement><region type="province">Région de Kantō</region></placeName></affiliation><affiliation></affiliation></author><author><name sortKey="Sone, Junko" sort="Sone, Junko" uniqKey="Sone J" first="Junko" last="Sone">Junko Sone</name><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Exploratory Chemistry Research Laboratories, Biological Research Laboratories, and Analytical and Metabolic ResearchLaboratories, Sankyo Company, Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan, and The Department ofInfectious Diseases, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku,Tokyo 108</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName><orgName type="university">Université de Tokyo</orgName><placeName><settlement type="city">Tokyo</settlement><region type="province">Région de Kantō</region></placeName></affiliation><affiliation></affiliation></author><author><name sortKey="Tsutsumi, Shinya" sort="Tsutsumi, Shinya" uniqKey="Tsutsumi S" first="Shinya" last="Tsutsumi">Shinya Tsutsumi</name><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Exploratory Chemistry Research Laboratories, Biological Research Laboratories, and Analytical and Metabolic ResearchLaboratories, Sankyo Company, Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan, and The Department ofInfectious Diseases, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku,Tokyo 108</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName><orgName type="university">Université de Tokyo</orgName><placeName><settlement type="city">Tokyo</settlement><region type="province">Région de Kantō</region></placeName></affiliation><affiliation></affiliation></author><author><name sortKey="Kosaka, Toshiyuki" sort="Kosaka, Toshiyuki" uniqKey="Kosaka T" first="Toshiyuki" last="Kosaka">Toshiyuki Kosaka</name><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Exploratory Chemistry Research Laboratories, Biological Research Laboratories, and Analytical and Metabolic ResearchLaboratories, Sankyo Company, Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan, and The Department ofInfectious Diseases, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku,Tokyo 108</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName><orgName type="university">Université de Tokyo</orgName><placeName><settlement type="city">Tokyo</settlement><region type="province">Région de Kantō</region></placeName></affiliation><affiliation></affiliation></author><author><name sortKey="Abe, Koji" sort="Abe, Koji" uniqKey="Abe K" first="Koji" last="Abe">Koji Abe</name><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Exploratory Chemistry Research Laboratories, Biological Research Laboratories, and Analytical and Metabolic ResearchLaboratories, Sankyo Company, Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan, and The Department ofInfectious Diseases, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku,Tokyo 108</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName><orgName type="university">Université de Tokyo</orgName><placeName><settlement type="city">Tokyo</settlement><region type="province">Région de Kantō</region></placeName></affiliation><affiliation></affiliation></author><author><name sortKey="Kimura, Satoshi" sort="Kimura, Satoshi" uniqKey="Kimura S" first="Satoshi" last="Kimura">Satoshi Kimura</name><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Exploratory Chemistry Research Laboratories, Biological Research Laboratories, and Analytical and Metabolic ResearchLaboratories, Sankyo Company, Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan, and The Department ofInfectious Diseases, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku,Tokyo 108</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName><orgName type="university">Université de Tokyo</orgName><placeName><settlement type="city">Tokyo</settlement><region type="province">Région de Kantō</region></placeName></affiliation><affiliation></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea> Current address: Department of Infection Control and Prevention,The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author><author><name sortKey="Shimada, Kaoru" sort="Shimada, Kaoru" uniqKey="Shimada K" first="Kaoru" last="Shimada">Kaoru Shimada</name><affiliation wicri:level="4"><country xml:lang="fr">Japon</country><wicri:regionArea>Exploratory Chemistry Research Laboratories, Biological Research Laboratories, and Analytical and Metabolic ResearchLaboratories, Sankyo Company, Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan, and The Department ofInfectious Diseases, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku,Tokyo 108</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName><orgName type="university">Université de Tokyo</orgName><placeName><settlement type="city">Tokyo</settlement><region type="province">Région de Kantō</region></placeName></affiliation><affiliation></affiliation><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea> Current address: Tokyo Senbai Hospital, 1-4-3 Mita, Minato-ku,Tokyo 108</wicri:regionArea><placeName><settlement type="city">Tokyo</settlement><region type="région">Région de Kantō</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Medicinal Chemistry</title><title level="j" type="abbrev">J. Med. Chem.</title><idno type="ISSN">0022-2623</idno><idno type="eISSN">1520-4804</idno><imprint><publisher>American Chemical Society</publisher><date type="e-published">1998</date><date type="published">1998</date><biblScope unit="vol">41</biblScope><biblScope unit="issue">19</biblScope><biblScope unit="page" from="3655">3655</biblScope><biblScope unit="page" to="3663">3663</biblScope></imprint><idno type="ISSN">0022-2623</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-2623</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>5′-End</term><term>Anti-HIV Agents (blood)</term><term>Anti-HIV Agents (chemical synthesis)</term><term>Anti-HIV Agents (chemistry)</term><term>Anti-HIV Agents (pharmacology)</term><term>Antisense DNA</term><term>Antiviral</term><term>Arene</term><term>Base pairing</term><term>Benzene derivatives</term><term>Biological fluid</term><term>Blood plasma</term><term>Cell Line, Transformed</term><term>Chain length</term><term>Chemical modification</term><term>Chemical stability</term><term>Chemical synthesis</term><term>Circular Dichroism</term><term>Circular dichroism</term><term>Deoxyribonucleotide</term><term>Drug Stability</term><term>Fluorene derivatives</term><term>HIV-1 (drug effects)</term><term>HIV-1 virus</term><term>Human</term><term>Humans</term><term>In vitro</term><term>Molecular Conformation</term><term>Molecular hybridization</term><term>Naphthalene derivatives</term><term>Oligodeoxyribonucleotide</term><term>Oligodeoxyribonucleotides (blood)</term><term>Oligodeoxyribonucleotides (chemical synthesis)</term><term>Oligodeoxyribonucleotides (chemistry)</term><term>Oligodeoxyribonucleotides (pharmacology)</term><term>Pyrene derivatives</term><term>Solutions</term><term>Structure activity relation</term><term>Structure-Activity Relationship</term><term>Xanthene derivatives</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Agents antiVIH ()</term><term>Agents antiVIH (pharmacologie)</term><term>Agents antiVIH (sang)</term><term>Agents antiVIH (synthèse chimique)</term><term>Conformation moléculaire</term><term>Dichroïsme circulaire</term><term>Humains</term><term>Lignée de cellules transformées</term><term>Oligodésoxyribonucléotides ()</term><term>Oligodésoxyribonucléotides (pharmacologie)</term><term>Oligodésoxyribonucléotides (sang)</term><term>Oligodésoxyribonucléotides (synthèse chimique)</term><term>Relation structure-activité</term><term>Solutions</term><term>Stabilité de médicament</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Anti-HIV Agents</term><term>Oligodeoxyribonucleotides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemical synthesis" xml:lang="en"><term>Anti-HIV Agents</term><term>Oligodeoxyribonucleotides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Anti-HIV Agents</term><term>Oligodeoxyribonucleotides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-HIV Agents</term><term>Oligodeoxyribonucleotides</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Agents antiVIH</term><term>Oligodésoxyribonucléotides</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Agents antiVIH</term><term>Oligodésoxyribonucléotides</term></keywords><keywords scheme="MESH" qualifier="synthèse chimique" xml:lang="fr"><term>Agents antiVIH</term><term>Oligodésoxyribonucléotides</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cell Line, Transformed</term><term>Circular Dichroism</term><term>Drug Stability</term><term>Humans</term><term>Molecular Conformation</term><term>Solutions</term><term>Structure-Activity Relationship</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Agents antiVIH</term><term>Conformation moléculaire</term><term>Dichroïsme circulaire</term><term>Humains</term><term>Lignée de cellules transformées</term><term>Oligodésoxyribonucléotides</term><term>Relation structure-activité</term><term>Solutions</term><term>Stabilité de médicament</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Antiviral</term><term>Appariement base</term><term>Arène</term><term>Benzène dérivé</term><term>DNA antisens</term><term>Dichroïsme circulaire</term><term>Désoxyribonucléotide</term><term>Extrémité 5′ P</term><term>Fluorène dérivé</term><term>Homme</term><term>Hybridation moléculaire</term><term>In vitro</term><term>Liquide biologique</term><term>Longueur chaîne</term><term>Modification chimique</term><term>Naphtalène dérivé</term><term>Oligodésoxyribonucléotide</term><term>Plasma sanguin</term><term>Pyrène dérivé</term><term>Relation structure activité</term><term>Stabilité chimique</term><term>Synthèse chimique</term><term>Virus HIV1</term><term>Xanthène dérivé</term><term>d(T-G-G-G-A-G)</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">A series of hexadeoxyribonucleotides (6-mers), d(TGGGAG), substituted with a variety of aromatic groups at the 5‘-end were synthesized and tested for anti-human immunodeficiency virus type 1 (HIV-1) activity. While unmodified d(TGGGAG) (31) had no anti-HIV-1 activity, compound 23 with a 3,4-di(benzyloxy)benzyl (DBB) group at the 5‘-end potently inhibited the HIV-1IIIB-induced cytopathicity of MT-4 cells in vitro (IC50 = 0.37 μM) without cytotoxicity up to 40 μM. A thermal denaturation study on the 5‘-end-substituted 6-mers by means of the circular dichroism (CD) spectra demonstrated that the aromatic substituent attached at the 5‘-end of the 6-mer strongly enhanced the formation of a parallel helical structure consisting of four strands (quadruplex). On the contrary, compound 36, in which one of the guanosines of 23 was replaced by a thymidine, did not form a quadruplex, thus exhibiting no anti-HIV-1 activity. Moreover, both compound 15, with a tert-butyldiphenylsilyl group solely at its 3‘-end, and compound 21, with a relatively small substituent, a benzyl group, at the 5‘-end, formed quadruplexes but had no anti-HIV-1 activity. These findings led us to the conclusion that both the quadruplex structure and the aromatic substituent with adequate size at the 5‘-end are crucial for the interaction of the 5‘-end-substituted 6-mers with the V3 loop as well as the CD4 binding site on viral gp120, resulting in anti-HIV-1 activity.</div></front></TEI><affiliations><list><country><li>Japon</li></country><region><li>Région de Kantō</li></region><settlement><li>Tokyo</li></settlement><orgName><li>Université de Tokyo</li></orgName></list><tree><country name="Japon"><region name="Région de Kantō"><name sortKey="Hotoda, Hitoshi" sort="Hotoda, Hitoshi" uniqKey="Hotoda H" first="Hitoshi" last="Hotoda">Hitoshi Hotoda</name></region><name sortKey="Abe, Koji" sort="Abe, Koji" uniqKey="Abe K" first="Koji" last="Abe">Koji Abe</name><name sortKey="Agatsuma, Toshinori" sort="Agatsuma, Toshinori" uniqKey="Agatsuma T" first="Toshinori" last="Agatsuma">Toshinori Agatsuma</name><name sortKey="Furukawa, Hidehiko" sort="Furukawa, Hidehiko" uniqKey="Furukawa H" first="Hidehiko" last="Furukawa">Hidehiko Furukawa</name><name sortKey="Hotoda, Hitoshi" sort="Hotoda, Hitoshi" uniqKey="Hotoda H" first="Hitoshi" last="Hotoda">Hitoshi Hotoda</name><name sortKey="Kaneko, Masakatsu" sort="Kaneko, Masakatsu" uniqKey="Kaneko M" first="Masakatsu" last="Kaneko">Masakatsu Kaneko</name><name sortKey="Kimura, Satoshi" sort="Kimura, Satoshi" uniqKey="Kimura S" first="Satoshi" last="Kimura">Satoshi Kimura</name><name sortKey="Kimura, Satoshi" sort="Kimura, Satoshi" uniqKey="Kimura S" first="Satoshi" last="Kimura">Satoshi Kimura</name><name sortKey="Koga, Rika" sort="Koga, Rika" uniqKey="Koga R" first="Rika" last="Koga">Rika Koga</name><name sortKey="Koizumi, Makoto" sort="Koizumi, Makoto" uniqKey="Koizumi M" first="Makoto" last="Koizumi">Makoto Koizumi</name><name sortKey="Kosaka, Toshiyuki" sort="Kosaka, Toshiyuki" uniqKey="Kosaka T" first="Toshiyuki" last="Kosaka">Toshiyuki Kosaka</name><name sortKey="Momota, Kenji" sort="Momota, Kenji" uniqKey="Momota K" first="Kenji" last="Momota">Kenji Momota</name><name sortKey="Nishigaki, Takashi" sort="Nishigaki, Takashi" uniqKey="Nishigaki T" first="Takashi" last="Nishigaki">Takashi Nishigaki</name><name sortKey="Ohmine, Toshinori" sort="Ohmine, Toshinori" uniqKey="Ohmine T" first="Toshinori" last="Ohmine">Toshinori Ohmine</name><name sortKey="Shimada, Kaoru" sort="Shimada, Kaoru" uniqKey="Shimada K" first="Kaoru" last="Shimada">Kaoru Shimada</name><name sortKey="Shimada, Kaoru" sort="Shimada, Kaoru" uniqKey="Shimada K" first="Kaoru" last="Shimada">Kaoru Shimada</name><name sortKey="Sone, Junko" sort="Sone, Junko" uniqKey="Sone J" first="Junko" last="Sone">Junko Sone</name><name sortKey="Tsutsumi, Shinya" sort="Tsutsumi, Shinya" uniqKey="Tsutsumi S" first="Shinya" last="Tsutsumi">Shinya Tsutsumi</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003A90 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003A90 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:EDFEF0F4A1559CD2994984A74C246B4A86698F91
|texte= Biologically Active Oligodeoxyribonucleotides. 5. 5‘-End-Substituted d(TGGGAG) Possesses Anti-Human Immunodeficiency Virus Type 1 Activity by Forming a G-Quadruplex Structure
}}
| This area was generated with Dilib version V0.6.33. |  |